View the Latest: Prescription Drugs
Filter
-
-
Briefing on State Medicaid Programs, the Recession and Health Reform
Event Date:EventThe Kaiser Family Foundation's Commission on Medicaid and the Uninsured (KCMU) held a 9:30 a.m. ET briefing on Thursday, September 30 to examine the challenges facing states as they continue to struggle with the lingering impacts of the recession and begin preparing to implement health reform.
-
The Crunch Continues: Medicaid Spending, Coverage and Policy in the Midst of a Recession
Event Date:EventThis annual 50-state survey finds that number of people on Medicaid and state spending on the program are climbing sharply as a result of the recession, straining state budgets and pressuring officials to curb costs despite increased financial help from the federal government through the American Recovery and Reinvestment Act (ARRA).
-
Policy Workshop on Formularies and Medicare
Event Date:EventThe Kaiser Family Foundation hosted a March 14, 2005 policy workshop on the use of drug formularies in the private sector and their potential implications for beneficiaries under the new Medicare drug benefit, set to go into effect January 1, 2006.
-
The Part D Experience: What are the Lessons for Broader Medicare Reform?
Event Date:EventLaunched in 2006, Medicare added a prescription drug benefit that relies entirely on private plans, while, for other benefits, beneficiaries have a choice between private health plans and traditional fee-for-service Medicare.
-
The State of Retiree Health Benefits: Historical Trends and Future Uncertainties
EventTricia Neuman, Vice President and Director of the Medicare Policy Project for the Kaiser Family Foundation, testified on Monday, May 17, at a
-
President Trump Proposes Codifying MFN Drug Pricing Deals But Key Details Are Missing
Quick TakeWhile codifying most-favored-nation drug pricing could be helpful for bringing more transparency to these arrangements and guaranteeing that drug companies will deliver on what they’ve promised, policymakers would need substantially more information to turn these backroom voluntary deals into law.
-
Perspectives from Employers on the Costs and Issues Associated with Covering GLP-1 Agonists for Weight Loss
Issue BriefWhile more large employers are covering GLP-1 drugs for weight loss, KFF's conversations with employers highlight concerns about the cost of these medications. Many of these employers have considered scaling back coverage of GLP-1 agonists for weight loss, or in some cases, employers are adding or strengthening coverage requirements.
-
The 4 Arguments You Will Hear Against Drug Price Negotiation
PerspectiveAs the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
-
How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs
Issue BriefThis brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.